TRANSLATING MOLECULAR PATHOLOGY INTO CANCER DIAGNOSTICS
Grant number: 1079329 | Funding period: 2015 - 2020
The aim of this research is focussed on translation of basic science through to the clinic by introducing novel cancer diagnostics and technologies. Other integral aims are to identify new changes in DNA and other cancer cell markers in patients, assess the clinical utility of these as biomarkers (surrogates of cancer behaviour) and to conduct novel clinical trials with newly identified molecular targets of cancer and new therapeutics and combinations to assess their efficacy.
Related publications (7)
Recurrent SPECC1L-NTRK fusions in pediatric sarcoma and brain tumors
Dong-Anh Khuong-Quang, Lauren M Brown, Marie Wong, Chelsea Mayoh, Alexandra Sexton-Oates, Amit Kumar, Mark Pinese, Sumanth Nagabushan, Loretta Lau, Louise E Ludlow, Andrew J Gifford, Michael Rodriguez, Jayesh Desai, Stephen B Fox, Michelle Haber, David S Ziegler, Jordan R Hansford, Glenn M Marshall, Mark J Cowley, Paul G Ekert
The identification of rearrangements driving expression of neurotrophic receptor tyrosine kinase (NTRK) family kinases in tumors h..
A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset ofNUTM1-rearranged tumors
Christopher R McEvoy, Holly Holliday, Niko Thio, Catherine Mitchell, David Y Choong, Bhargavi Yellapu, Hui San Leong, Huiling Xu, Stephen Lade, Judy Browning, Elena A Takano, David J Byrne, Anthony J Gill, Cuong P Duong, Jason Li, Andrew P Fellowes, Stephen B Fox, Alexander Swarbrick, Owen WJ Prall
Most NUTM1-rearranged neoplasms (NRNs) have fusions between NUTM1 and BRD (bromodomain-containing) family members and are termed N..
The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density
Dane Cheasley, Lisa Devereux, Siobhan Hughes, Carolyn Nickson, Pietro Procopio, Grant Lee, Na Li, Vicki Pridmore, Kenneth Elder, G Bruce Mann, Tanjina Kader, Simone M Rowley, Stephen B Fox, David Byrne, Hugo Saunders, Kenji M Fujihara, Belle Lim, Kylie L Gorringe, Ian G Campbell
Mammographic density (MD) influences breast cancer risk, but how this is mediated is unknown. Molecular differences between breast..
Molecular comparison of interval and screen-detected breast cancers
Dane Cheasley, Na Li, Simone M Rowley, Kenneth Elder, G Bruce Mann, Sherene Loi, Peter Savas, David L Goode, Tanjina Kader, Magnus Zethoven, Tim Semple, Stephen B Fox, Jia-Min Pang, David Byrne, Lisa Devereux, Carolyn Nickson, Pietro Procopio, Grant Lee, Siobhan Hughes, Hugo Saunders
Breast cancer (BC) diagnosed after a negative mammogram but prior to the next screening episode is termed an 'interval BC' (IBC). ..
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
Peter Savas, Balaji Virassamy, Chengzhong Ye, Agus Salim, Christopher P Mintoff, Franco Caramia, Roberto Salgado, David J Byrne, Zhi L Teo, Sathana Dushyanthen, Ann Byrne, Lironne Wein, Stephen J Luen, Catherine Poliness, Sophie S Nightingale, Anita S Skandarajah, David E Gyorki, Chantel M Thornton, Paul A Beavis, Stephen B Fox
The quantity of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is a robust prognostic factor for improved patient sur..
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
Shona Hendry, David J Byrne, Gavin M Wright, Richard J Young, Sue Sturrock, Wendy A Cooper, Stephen B Fox
INTRODUCTION: Four different programmed death ligand 1 immunohistochemical assays are approved or in development as companion or c..
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Emma Nolan, Peter Savas, Antonia N Policheni, Phillip K Darcy, Francois Vaillant, Christopher P Mintoff, Sathana Dushyanthen, Mariam Mansour, Jia-Min B Pang, Stephen B Fox, Charles M Perou, Jane E Visvader, Daniel HD Gray, Sherene Loi, Geoffrey J Lindeman
Immune checkpoint inhibitors have emerged as a potent new class of anticancer therapy. They have changed the treatment landscape f..